NCT03231657View on ClinicalTrials.gov

Randomizated Open-label Control Trial to Evaluate if the Incorporation of sFlt1/PlGF Ratio in the Diagnosis and Classification of PE Improves Maternal and Perinatal Outcomes in Women With the Suspicion of the Disease

NACompletedINTERVENTIONAL

Enrollment

2,536

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

June 21, 2022

Study Completion Date

November 11, 2023

Conditions

Preeclampsia

Interventions

DIAGNOSTIC_TEST

Placental biomarkers

sFlt1 and P1GF levels and sFlt1/PlGF ratio

Trial Locations (1)

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors

collaborator

Carlos III Health Institute

OTHER_GOV

collaborator

Spanish Clinical Research Network - SCReN

NETWORK

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT03231657 - Randomizated Open-label Control Trial to Evaluate if the Incorporation of sFlt1/PlGF Ratio in the Diagnosis and Classification of PE Improves Maternal and Perinatal Outcomes in Women With the Suspicion of the Disease | Biotech Hunter | Biotech Hunter